These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 27394191)
1. Safety and immunogenicity of RTS,S/AS01 malaria vaccine in infants and children with WHO stage 1 or 2 HIV disease: a randomised, double-blind, controlled trial. Otieno L; Oneko M; Otieno W; Abuodha J; Owino E; Odero C; Mendoza YG; Andagalu B; Awino N; Ivinson K; Heerwegh D; Otsyula N; Oziemkowska M; Usuf EA; Otieno A; Otieno K; Leboulleux D; Leach A; Oyieko J; Slutsker L; Lievens M; Cowden J; Lapierre D; Kariuki S; Ogutu B; Vekemans J; Hamel MJ Lancet Infect Dis; 2016 Oct; 16(10):1134-1144. PubMed ID: 27394191 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. RTS,S Clinical Trials Partnership Lancet; 2015 Jul; 386(9988):31-45. PubMed ID: 25913272 [TBL] [Abstract][Full Text] [Related]
3. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Olivier A; Benns S; Olomi R; Msham S; Lang T; Gould J; Hallez K; Guerra Y; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Dekker D; Malle L; Ismael S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; Bejon P; von Seidlein L PLoS One; 2010 Nov; 5(11):e14090. PubMed ID: 21124768 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa. Otieno L; Guerra Mendoza Y; Adjei S; Agbenyega T; Agnandji ST; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kariuki S; Kremsner P; Lanaspa M; Lell B; Lievens M; Lusingu J; Malabeja A; Masoud NS; Mtoro AT; Njuguna P; Ofori-Anyinam O; Otieno GA; Otieno W; Owusu-Agyei S; Schuerman L; Sorgho H; Tanner M; Tinto H; Valea I; Vandoolaeghe P; Sacarlal J; Oneko M Vaccine; 2020 Jan; 38(4):897-906. PubMed ID: 31708182 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519 [TBL] [Abstract][Full Text] [Related]
6. Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Leach A; Vekemans J; Lievens M; Ofori-Anyinam O; Cahill C; Owusu-Agyei S; Abdulla S; Macete E; Njuguna P; Savarese B; Loucq C; Ballou WR; Malar J; 2011 Aug; 10():224. PubMed ID: 21816029 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. RTS,S Clinical Trials Partnership PLoS Med; 2014 Jul; 11(7):e1001685. PubMed ID: 25072396 [TBL] [Abstract][Full Text] [Related]
17. Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. Olotu A; Fegan G; Wambua J; Nyangweso G; Leach A; Lievens M; Kaslow DC; Njuguna P; Marsh K; Bejon P N Engl J Med; 2016 Jun; 374(26):2519-29. PubMed ID: 27355532 [TBL] [Abstract][Full Text] [Related]
18. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
19. Genotypic analysis of RTS,S/AS01 Juraska M; Early AM; Li L; Schaffner SF; Lievens M; Khorgade A; Simpkins B; Hejazi NS; Benkeser D; Wang Q; Mercer LD; Adjei S; Agbenyega T; Anderson S; Ansong D; Bii DK; Buabeng PBY; English S; Fitzgerald N; Grimsby J; Kariuki SK; Otieno K; Roman F; Samuels AM; Westercamp N; Ockenhouse CF; Ofori-Anyinam O; Lee CK; MacInnis BL; Wirth DF; Gilbert PB; Neafsey DE Lancet Infect Dis; 2024 Sep; 24(9):1025-1036. PubMed ID: 38723650 [TBL] [Abstract][Full Text] [Related]
20. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. Lell B; Agnandji S; von Glasenapp I; Haertle S; Oyakhiromen S; Issifou S; Vekemans J; Leach A; Lievens M; Dubois MC; Demoitie MA; Carter T; Villafana T; Ballou WR; Cohen J; Kremsner PG PLoS One; 2009 Oct; 4(10):e7611. PubMed ID: 19859560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]